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Bock, Johannes G.M. Burgerhof, Jourik A. Gietema, Johannes A. Langendijk, John H. Maduro, and Anne P.G
Crijns
A B S T R A C T
Purpose
A relationship betweenmean heart dose (MHD) and acute coronary event (ACE) rate was reported in
a study of patients with breast cancer (BC). The main objective of our cohort study was to validate
this relationship and investigate if other dose-distribution parameters are better predictors for ACEs
than MHD.
Patients and Methods
The cohort consisted of 910 consecutive female patients with BC treated with radiotherapy (RT)
after breast-conserving surgery. The primary end point was cumulative incidence of ACEs within
9 years of follow-up. Both MHD and various dose-distribution parameters of the cardiac sub-
structures were collected from three-dimensional computed tomography planning data.
Results
The median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy). The median follow-up time was 7.6 years
(range, 0.1 to 10.1 years), duringwhich 30 patients experienced an ACE. The cumulative incidence of
ACE increased by 16.5% per Gy (95% CI, 0.6 to 35.0; P = .042). Analysis showed that the volume of
the left ventricle receiving 5 Gy (LV-V5) was the most important prognostic dose-volume parameter.
The most optimal multivariable normal tissue complication probability model for ACEs consisted of
LV-V5, age, and weighted ACE risk score per patient (c-statistic, 0.83; 95% CI, 0.75 to 0.91).
Conclusion
A signiﬁcant dose-effect relationship was found for ACEs within 9 years after RT. Using MHD, the
relative increase per Gywas similar to that reported in the previous study. In addition, LV-V5 seemed
to be a better predictor for ACEs than MHD. This study conﬁrms the importance of reducing ex-
posure of the heart to radiation to avoid excess risk of ACEs after radiotherapy for BC.
J Clin Oncol 35:1171-1178. © 2017 by American Society of Clinical Oncology. Licensed under the
Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/
INTRODUCTION
The number of breast cancer (BC) survivors is
increasing as a result of rising incidence, earlier
diagnosis, and better treatment results.1,2 Al-
though adjuvant radiotherapy (RT) after sur-
gery for BC improves locoregional control and
overall survival, incidental exposure of the
heart to radiation increases the risk of RT-
induced cardiac toxicity.3-5 Consequently, the
prevalence of BC survivors at risk for long-term
RT-induced cardiac toxicity is increasing and
may have a signiﬁcant impact on health-related
quality of life.
Darby et al6 demonstrated a dose-effect
relationship based on the mean heart dose
(MHD) to the whole heart. They found a rel-
ative increase of 7.4% per Gy of MHD in the
rate of major acute coronary events (ACEs) for
the entire follow-up period. Conﬁning the
analysis to the ﬁrst 9 years after radiation ex-
posure, a relative increase of approximately
16% per Gy was found. However, the study
had some limitations: its design (case-control
study), use of outdated RT technologies, and
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use of reconstructed MHDs derived from two-dimensional
data.
Therefore, the ﬁrst aim of our study was to validate the
ﬁndings of Darby et al6 with an independent cohort of consecutive
patients with BC based on individual three-dimensional (3D) dose
distributions derived from computed tomography (CT) planning
scans. The second aim of this cohort study was to investigate
whether other dose-distribution parameters could better predict




This study population was composed of a consecutive series of female
patients with BC treated with RTafter breast-conserving surgery for stage I
to III invasive adenocarcinoma or carcinoma in situ from January 2005 to
December 2008 in our hospital (Appendix Fig A1, online only). Patients
with BC were eligible for inclusion only if CT-based RT planning data were
available. Patients were excluded if they had a history of other malignancies
or had received prior RT or treatment with neoadjuvant chemotherapy.
The primary end point was an ACE, deﬁned as a diagnosis of myocardial
infarction (International Classiﬁcation of Diseases, 10th Revision, codes
121 to 124), coronary revascularization, or death resulting from ischemic
heart disease (codes 120 to 125) after completion of treatment. Pre-
treatment risk factors for ACEs that were taken into account included
history of ischemic heart disease, any other cardiac disease, hypertension,
chronic obstructive pulmonary disease, pulmonary embolism, diabetes,
current smoker status, and body mass index $ 30 kg/m2. Both the end
point and pretreatment risk factors were similar to those deﬁned by Darby
et al.6
Data Collection
Patient characteristics, treatment plans, follow-up data, and in-
formation on cardiac risk factors and cardiac end points were retro-
spectively extracted from patient records of the Department of Radiation
Oncology (University Medical Center Groningen, University of Gronin-
gen, Groningen, the Netherlands). Incomplete patient data were supple-
mented with information derived from general practitioners’ (GPs’)
records. To this end, surviving patients were informed about the study by
letter and asked for their written informed consent. GPs of deceased
patients were allowed to provide relevant information directly, because GPs
have legal governance over deceased patients’ records in the Netherlands.
The aforementioned procedure was approved by the medical ethical
committee of the University Medical Center Groningen.
Data Definitions
The baseline date was deﬁned as the ﬁrst day of breast irradiation.
Patient event times were censored in cases where a new radiation treatment
was delivered in the follow-up period, in cases of death, or at the end of
follow-up time. The follow-up interval was deﬁned as the time between
baseline and censoring date or date of event. Patient information was
collected until the last known date of medical follow-up or last known
information obtained from the GP.
Radiation Dosimetry
Irradiation of the breast for all patients was performed with 3D
conformal RT using CT-based planning, as described previously.7 All
treatment plans were calculated using heterogeneity corrections. Beam
conﬁguration comprised tangential ﬁelds and additional beams for op-
timization of planning target volume coverage, as well as for minimization
of the dose to the heart, lungs, and contralateral breast. A dose of 50.4 Gy
was prescribed for the whole breast in 28 fractions, with a simultaneous
integrated boost dose of 14 or 16.8 Gy in the same 28 fractions, depending
on pathologic risk factors. The heart and its substructures, including the
left ventricle (LV), left atrium, right ventricle, and right atrium, were
recontoured with a multiatlas automatic segmentation tool of the heart
developed in house based on the atlas by Feng et al8 (Mirada RTx [version
1.6]; Mirada Medical, Oxford, United Kingdom).9 Automatic segmenta-
tion reduces interobserver variability in contouring organs at risk and
therefore generates more consistent data to create normal tissue com-
plication probability (NTCP) models.10,11 With the delineated volumes, it
was possible to calculate the exact planned radiation dose to the different
volumes. This so-called dose-volume histogram showed the relationship
between the dose in Gy to the volume percentage of the structure of
interest.12,13 With the dose of the individual patients, the dose-effect re-
lationship could be calculated independently of RT technique or treatment
volume. Finally, the planned dose-distribution parameters for the whole
heart and its substructures were extracted from our treatment planning
system (Pinnacle [version 9.1]; Philips Radiation Oncology, Fitchburg,
WI).
Statistical Analysis
The cumulative incidence of ACEs was analyzed using the Kaplan-
Meier method. To validate the model of Darby et al,6 a multivariable Cox
regression analysis was used, including the same risk factors and end point.
Model performance was tested for calibration using the Hosmer-Lemeshow
(HL) test, and discrimination was tested using the c-statistic.
The most relevant dose-distribution parameters for the different
cardiac substructures were identiﬁed by comparing the mean dose-
distribution parameters of patient cases (patients who experienced an
ACE) with noncases (patients who did not). To this end, we calculated the
mean V(x) in bins of 5 Gy for both patient cases and noncases, where V(x)
refers to the relative volume (in percentage) of the heart or cardiac sub-
structure that received x Gy. Differences between the two groups regarding
all mean dose-distribution parameters were tested with a t test or Wilcoxon
rank sum test whenever appropriate. The dichotomous variable (no risk
factor v one or more risk factors) was replaced by a weighted ACE risk score
per patient. To this end, we ﬁrst investigated which risk factors were sig-
niﬁcantly associated with the incidence of ACEs by using univariable Cox
regression analysis and then performed a multivariable analysis taking into
account only the signiﬁcant cardiac risk factors. For the risk factors that were
signiﬁcantly associated with ACEs in the multivariable analysis, the re-
gression coefﬁcients were calculated and used for the weighted sum of the
risk factor(s) per patient. In correspondence with Darby et al,6 age was
entered into themodel as well. Because the number of events was limited, we
decided not to add more than these three factors to the model to prevent
overﬁtting.14,15 For internal validation and adjustment for possible internal
optimism for both the c-statistics and some estimators, bootstrapping was
performed by using 1,000 random subsets. Model performance was tested
for calibration using the HL test. Finally, the excess risk of an ACE resulting
from RT was calculated via the individual patient risk based on the model
minus the individual patient risk assuming the LV receiving 5 Gy (LV-V5)




A total of 910 patients were included in this study. The
characteristics of these patients are summarized in Table 1. The
median age of all patients was 59 years (range, 26 to 84 years). At
baseline, more than half of the patients had one ormore risk factors
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for ACEs. The median follow-up time was 7.6 years (range, 0.1 to
10.1 years).
More detailed information about the distribution of MHD
and the univariable analysis between MHD and the end point
ACE is provided in Appendix Table A1 (online only), Appendix
Figures A2 to A4 (online only), and Appendix Figure A5 (online
only), and information about patients experiencing an event is
listed in Appendix Table A2 (online only). In total, 30 patients
(3.3%) developed an ACE during follow-up, 10 of whom died as
a result of ischemic heart disease. In the ﬁrst 5 years, 17 patients
were diagnosed with ACEs. The 5- and 9-year cumulative in-
cidences of ACEs were 1.9% (95% CI, 0.9% to 2.9%) and 3.9%
(95% CI, 2.3% to 5.5%), respectively (Appendix Fig A6, online
only).
Validation
To validate the model of Darby et al,6 a multivariable Cox
regression model was created using the same prognostic factors
(ie, age, MHD, and presence of pretreatment risk factors for ACEs,
Table 1. Patient Clinical Characteristics at Baseline (N = 910)
Characteristic No. of Patients % P*
















$ 1 523 57.5
History of (cardiac) comorbidity































, 30 832 91.4
$ 30 78 8.6
Tumor characteristic
Pathologic T stage
T1 664 73.0 .948
T $ 2 240 26.4 .745
Unknown 6 0.7 .976
Pathologic N stage
N0i+ 617 67.8 .782
N1 208 22.9 .220
N2 46 5.1 .724
N3 7 0.8 .979
Nx/unknown 32 3.5 .915






(continued in next column)
Table 1. Patient Clinical Characteristics at Baseline (N = 910) (continued)



















Abbreviations: ACE, acute coronary event; BC, breast cancer; BMI, body mass
index; COPD, chronic obstructive pulmonary disease; MHD, mean heart dose;
NA, not applicable; RT, radiotherapy.
*P value between the variable and occurrence of an ACE, calculated using
univariable Cox regression analysis.
†Risk factors according to Darby et al6 included: history of ischemic heart
disease, history of circulatory disease other than ischemic heart disease, history
of diabetes, history of COPD, current smoker, and BMI $ 30 kg/m2. ACE was
deﬁned according to Darby et al as a diagnosis of myocardial infarction (In-
ternational Classiﬁcation of Diseases, 10th Revision, codes 121 to 124), coronary
revascularization, or death resulting from ischemic heart disease (codes 120 to
125).
‡Women with a history of ischemic heart disease were deﬁned as those for
whom myocardial infarction or angina was documented in their medical record.
§Hypertension was considered when the systolic blood pressure was $ 140
mmHg and/or when the diastolic blood pressure was $ 90 mmHg.
kCOPD of any Global Initiative on Obstructive Lung Disease class.
¶Diabetes of any type.
#Adjuvant systemic therapy was indicated in patients with high-risk node-
negative tumors and in patients with node-positive disease. In 55 patients,
detailed information about chemotherapy treatment was not clearly registered.
In total, 248 patients received anthracyclines. In this series, 26 patients were
treated with taxane-based chemotherapy. Trastuzumab (n = 47) was recom-
mended for all patients with tumors overexpressing the human epidermal
growth factor receptor 2.
jco.org © 2017 by American Society of Clinical Oncology 1173
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categorized as either none or one or more at baseline). The cu-
mulative incidence of ACEs increased by 16.5% per Gy (P = .042)
within 9 years of RT (Table 2).
On the basis of this model, the 9-year excess cumulative risk
(CER9y) can be calculated using the following equations:
1. The linear predictor LPMHD-model = (0.153 3 MHD) +
(0.087 3 AGE) + (1.821 3 RISK), in which MHD = mean
heart dose in Gy, AGE = age in years, and RISK = 0 when no
risk factors for ACEs are present at baseline and RISK = 1 if
one or more risk factors at baseline are present.
2. The cumulative incidence for each individual patient at 9 years
(CI9y) can then be calculated using the following equation:
CI9y = 1 – [EXP(20.000025 3 LPMHD-model)].
3. The 9-year excess cumulative risk (CER9y) can then be cal-
culated by using Equation 2 minus the CI9y assuming an
MHD of 0 Gy (CI9y-0Gy): CER9y = CI9y – CI9y-0Gy.
The HL test showed no signiﬁcant difference between ex-
pected and observed rates of ACEs (P = .406), indicating good
calibration. Model discrimination was good, with a c-statistic of
0.79 (95% CI, 0.71 to 0.87). The mean predicted CI9y for the entire
population was 4.0%, which was in agreement with the CI9y ac-
tually observed: 3.9%.
To get an impression of the early risk of ACEs, a model for the
ﬁrst 5 years after RT (Table 2) was tested separately. Using the same
risk factors and end point as those of Darby et al,6 an increase of
24.6% in the rate of ACEs per Gy of MHD was found for the
complete follow-up period of 5 years.
Model Optimization
To identify the most relevant dose-distribution parameters,
we compared the mean dose parameters of the patient cases
(patients who experienced an ACE) with noncases (patients who
did not). Figure 1 shows the differences between the mean dose-
distribution parameters per cardiac substructure that were
tested for signiﬁcance. The largest difference was found for LV-
V5. In the univariable Cox regression analysis, summarized in
Table 3, LV-V5 was signiﬁcantly associated with the cumulative
incidence of ACEs, with a hazard ratio of 1.016 (95% CI, 1.002
to 1.030; P = .016). Because of this strong association, we chose
to include LV-V5 in the model. Replacement of MHD with LV-
V5 resulted in an improvement of the c-statistic of the NTCP
model to 0.80 (95% CI, 0.72 to 0.88). We also tested the re-
lationship of the maximum dose to the heart with the cumu-
lative incidence of ACEs using a univariable Cox regression
Table 2. Multivariable NTCP Model for Cumulative Incidence of ACEs
Variable B SE HR 95% CI for HR P
Within ﬁrst 9 years after RT
Age 0.087 0.020 1.090 1.049 to 1.133 , .001
MHD* 0.153 0.075 1.165 1.006 to 1.350 .042
Risk factor† 1.821 0.619 6.180 1.837 to 20.790 .003
Within ﬁrst 5 years after RT
Age 0.113 0.028 1.120 1.061 to 1.182 , .001
MHD* 0.220 0.093 1.246 1.037 to 1.495 .019
Risk factor† 1.491 0.758 4.443 1.006 to 19.622 .049
Abbreviations: ACE, acute coronary event; HR, hazard ratio; MHD, mean heart dose; NTCP, normal tissue complication probability; RT, radiotherapy.
*MHD per Gy based on individual three-dimensional dose-volume data obtained from computed tomography planning scans.
†Deﬁned by Darby et al6 as a dichotomous variable: none versus one or more risk factors.
Dose-distribution
parameter No ACE ACE
Difference between ACE
and no ACE





























































































































































Fig 1. Comparison of the mean dose distribution parameters of patient cases (patients who experienced an acute coronary event [ACE]) and noncases (those who did
not) and calculation of the differences. NOTE. All data are given as the relative volumes (%) of the cardiac substructures that received (x) Gy or more in bins of 5 Gy. LA, left
atrium; LV, left ventricle; RA, right atrium; RV, right ventricle.
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analysis and found it was not signiﬁcantly associated with ACEs
(data not shown).
To further optimize the NTCP model based on LV-V5, the
dichotomous variable (no risk factor v one or more risk factors)
was replaced with a weighted ACE risk score per patient. Because
there were only 30 events, LV-V5, age, and weighted ACE risk score
per patient based on the regression coefﬁcient of the signiﬁcant risk
factors for ACEs (0.8 for diabetes, 1.4 for hypertension, and 1.8 for
history of ischemic cardiac events) were entered into the multi-
variable model. The ﬁnal multivariable NTCP model summarized
in Table 3 is corrected for optimism.
On the basis of this model, the 9-year excess cumulative risk
(CER9y) can be calculated using the following equations:
1. The linear predictor LPLV-V5-model = (0.017 3 LV-V5) +
(0.063 3 AGE) + (0.711 3 RISKSCORE), in which LV-V5 =
LV-V5 in %, AGE = age in years, and RISKSCORE = weighted
ACE risk score (0 for no risk factors; add 0.8 in case of di-
abetes, add 1.4 in case of hypertension, and add 1.8 in case of
ischemic cardiac events before RT).
2. The cumulative incidence for each individual patient at 9 years
(CI9y) can then be calculated using the following equation:
CI9y = 1 – [EXP(20.000223 3 LPLV-V5-model)].
3. The 9-year excess cumulative risk (CER9y) can then be cal-
culated by using Equation 2 minus the CI9y assuming an
MHD of 0 Gy (CI9y-0Gy): CER9y = CI9y – CI9y-0Gy.
The mean predicted CI9y for the entire population was 3.5%,
whichwas in agreement with the CI9y actually observed: 3.9%. This
modiﬁed model showed good agreement between expected and
observed rates of ACEs (HL test P = .380). Discrimination of the
ﬁnal model in terms of the c-statistic showed good results at 0.83
(95% CI, 0.75 to 0.91), which was signiﬁcantly better than that in
the MHD model (P = .042).
Table 3. Univariable and Multivariable NTCP Models for Cumulative Incidence of ACEs Within First 9 Years After RT After Correction for Overﬁtting
Variable B SE HR 95% CI for HR P
Univariable analysis LV-V5
LV-V5* 0.016 0.007 1.016 1.002 to 1.030 .016
Final multivariable NTCP model
LV-V5* 0.017 0.009 1.017 0.999 to 1.035 .041
Age 0.063 0.026 1.065 1.014 to 1.116 .010
Weighted ACE risk score 0.711 0.187 2.036 1.669 to 2.403 .001
Abbreviations: ACE, acute coronary event; HR, hazard ratio; LV-V5, left-ventricle receiving 5 Gy; NTCP, normal tissue complication probability; RT, radiotherapy.
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Fig 2. Excess risk of an acute coronary event (ACE) depending on the mean heart dose (MHD) in volume percentage calculated per age category and (A) absence or (B)
presence of cardiac risk factors.
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The excess cumulative risk related to RT was 1.13% within 9
years of follow-up, indicating that approximately 10 patients in this
BC cohort experienced an ACE that could be attributed to RT. The
excess risk for the occurrence of an ACE, depending on the mean
dose, is shown in Figure 2 and based on the LV-V5 in Figure 3.
DISCUSSION
To our knowledge, this is the ﬁrst study to validate the model
published by Darby et al6 in an independent cohort using indi-
vidual 3D CT planning data. Using exactly the same risk factors
and end point as Darby et al, we found an increase of 16.5% (95%
CI, 0.6 to 35.0) in the cumulative incidence of ACEs per Gy of
radiation to the whole heart in the ﬁrst 9 years after treatment.
These results are consistent with the hazard ratios of 16.3% in-
crease per Gy, as observed by Darby et al in the ﬁrst 4 years of
follow-up, and 15.5% increase in the next 5 to 9 years after RT.
Furthermore, our study suggests that the NTCP model for ACEs
could be improved by using LV-V5 instead of MHD. Model
performance showed good results in terms of calibration and
discrimination.
An NTCP model is a term generally used in radiation on-
cology, which refers to any prediction model describing the re-
lationship between 3D dose-distribution parameters of normal
tissues and a complication end point. In radiotherapy, NTCP
models are generally used to estimate the risks of adverse effects, as
well as to optimize dose distributions for individual patients by
minimizing the most relevant dose metrics derived from NTCP
models.16 To enhance the clinical utility of prediction models, it is
highly recommended that the performance of the model be
evaluated in an independent data set.17 Despite differences with
regard to study design (case-control v cohort study), irradiation
technique, estimated dose distributions (reconstructed MHD v 3D
planning CT based), timeframe, and nationality, the results found
in our study are in line with those reported by Darby et al.6



















































































































Fig 3. Excess risk of an acute coronary event (ACE) depending on the mean V5 of the left ventricle (LV-V5) in volume percentage calculated per age category and risk
factor: (A) no cardiac risk factors, (B) diabetes, (C) hypertension, and (D) ischemic cardiac event. For example, a patient age 70 years with an LV-V5 of 50% and no cardiac
risk factors has an excess risk of 2.52% of developing an ACE within 9 years after radiotherapy. If the same patient had a history of ischemic heart disease, with a similar
value for LV-V5, the excess risk would increase to 8.42%.
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a TRIPOD (Transparent Reporting of a Multivariable Prediction
Model for Individual Prognosis or Diagnosis) type IV prediction
model, the performance of which has been evaluated in an in-
dependent data set.17 The results of case-control studies, as re-
ported by Darby et al, provide only relative risk against baseline
risk, which requires other prediction models to assess these
baseline risks. Because our multivariable externally validated
model (Table 2) was based on a cohort study, it allows for a direct
risk estimation of ACEs for individual patients with BC. However,
because we were not able to externally validate the LV-V5 model,
this model should be regarded as TRIPOD type Ib, which requires
external validation ﬁrst before it can be used in routine clinical
practice.
Our dose-distribution analysis (Fig 1) showed that the LV
received the highest dose of all cardiac structures, which is mainly
because of the anatomic location of the LV in relation to the breasts
and treatment technique, which may increase statistical power.
The analysis comparing the dose-distribution parameters between
patient cases and noncases also revealed large differences, even for
lower dose levels (eg, LV-V2 to -V4; data not shown). LV-V5 was
eventually chosen because this dose-distribution parameter has
been widely used in many other recent reports.18-22
As shown in a recent study, heart doses from RT for BC vary
widely, even among seemingly similar regimens.23 Therefore, we
chose to use an automatic delineation tool to exclude interobserver
variability.8,24 Furthermore, we used individual dose-volume data,
which account for differences in anatomy and treatment volume.
It has long been assumed that the clinical events of incidental
cardiac irradiation occur after more than 10 years.25-29 One of the
biologic mechanisms leading to radiation-induced ACEs is
accelerated atherosclerosis.30-32 However, in our analysis, a dose-
effect relationship was found for events occurring within the ﬁrst
5 years after radiation exposure. This early risk is consistent with
that reported by Darby et al6 and that seen in other research in
patients with Hodgkin lymphoma.33 However, other studies found
only a small effect in 6 to 10 years after treatment, when the
internal mammary nodes were not treated.34,35 When these nodes
were treated, the occurrence of cardiac damage was found within
5 years.36 Given these results, and setting aside the relatively
slowly progressing phenomenon of atherosclerosis, other bi-
ologic mechanisms are most likely responsible for the relatively
early cardiac events occurring after RT (eg, microvascular damage,
impairment in myocardial perfusion and/or fatty acid metabolism,
and many more).37-41 Studies investigating these underlying
mechanisms for early RT-induced cardiac damage using modern
imaging techniques are currently under way.42
A limitation of our study is the relatively small number of
ACEs. Because 3D conformal RT at our hospital was clinically
introduced in 2005, the follow-up time was relatively short.
To prevent overﬁtting by using too many candidate variables
in relation to the number of events, we included only two other
prognostic factors, besides the dose-distribution parameter: clin-
ical risk factors for ACEs and age, based on the fact that these are
considered the most important predictors for ACEs.43 Conse-
quently, the effects of other potential confounders could not be
taken into account, such as the addition of systemic agents that
could also cause cardiac toxicity.44,45
In conclusion, the MHD-based NTCP model for ACEs has
been independently validated using 3D dose-distribution data
among patients with BC treated with postoperative RT. Radiation
dose to the heart is an important risk factor for ACEs in BC
survivors. Model performance was signiﬁcantly improved by
replacingMHDwith LV-V5 and using the weighted ACE risk score,
but this optimized model requires further external validation in an
independent data set.
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Appendix




Total Left-Sided BC Right-Sided BC
Age at BC diagnosis, years
18-35 2.34 (0.98-12.68) 4.39 (1.08-12.68) 1.26 (0.98-2.37)
36-45 2.29 (0.63-13.75) 4.73 (1.85-13.75) 1.32 (0.63-3.19)
46-55 1.99 (0.51-12.37) 4.58 (1.27-12.37) 1.32 (0.51-3.63)
56-65 2.57 (0.62-15.25) 4.48 (1.17-15.25) 1.32 (0.62-6.87)
66-75 2.31 (0.67-10.81) 4.12 (0.99-10.81) 1.31 (0.67-4.46)
$ 76 2.99 (0.75-9.46) 4.42 (1.48-9.46) 1.25 (0.75-3.95)
No. of risk factors for ACE at baseline*
0 2.35 (0.62-15.25) 4.66 (1.08-15.25) 1.35 (0.62-6.87)
$ 1 2.38 (0.51-13.75) 4.19 (0.99-13.75) 1.28 (0.51-4.46)
History of (cardiac) comorbidity
Ischemic heart disease† 3.22 (0.67-6.55) 3.81 (1.81-6.55) 1.24 (0.67-4.12)
Yes 2.35 (0.51-15.25) 4.48 (0.99-15.25) 1.31 (0.51-6.87)
No
Heart failure 2.45 (1.19-8.92) 2.98 (1.81-8.92) 1.92 (1.19-4.12)
Yes 2.37 (0.51-15.25) 4.44 (0.99-15.25) 1.31 (0.51-6.87)
No
Cardiac valve disease 2.65 (0.64-7.47) 4.97 (2.24-7.47) 1.56 (0.64-4.12)
Yes 2.35 (0.51-15.25) 4.41 (0.99-15.25) 1.31 (0.51-6.87)
No
Hypertension‡ 2.68 (0.51-11.22) 4.45 (0.99-11.22) 1.27 (0.51-4.12)
Yes 2.26 (0.62-15.25) 4.42 (1.08-15.25) 1.33 (0.62-6.87)
No
COPD§
Yes 2.39 (0.64-9.35) 3.30 (1.27-9.35) 1.38 (0.64-3.96)
No 2.36 (0.51-15.25) 4.49 (0.99-15.25) 1.31 (0.51-6.87)
Pulmonary embolism
Yes 2.35 (0.72-5.58) 5.26 (2.35-5.58) 1.19 (0.72-1.56)
No 2.37 (0.51-15.25) 4.43 (0.99-15.25) 1.31 (0.51-6.87)
Diabetesk
Yes 3.30 (0.68-8.92) 4.55 (2.65-8.92) 1.23 (0.68-3.96)
No 2.33 (0.51-15.25) 4.44 (0.99-15.25) 1.32 (0.51-6.87)
Lifestyle risk factors at baseline
Current smoker
Yes 1.99 (0.64-13.75) 3.92 (1.17-13.75) 1.27 (0.64-3.63)
No 2.46 (0.51-15.25) 4.52 (0.99-15.25) 1.33 (0.51-6.87)
BMI, kg/m2
, 30 2.37 (0.62-15.25) 4.45 (1.08-15.25) 1.31 (0.62-6.87)
$ 30 2.25 (0.51-9.62) 4.27 (0.99-9.62) 1.39 (0.51-4.46)
Tumor characteristic
Pathologic T stage
T1 2.31 (0.64-15.25) 4.40 (0.99-15.25) 1.31 (0.64-6.87)
T $ 2 2.55 (0.51-12.68) 4.48 (1.08-12.68) 1.31 (0.51-4.46)
Unknown 1.35 (0.93-8.64) 4.91 (1.17-8.64) 1.35 (0.93-2.04)
Pathologic N stage
N0i+ 2.38 (0.62-15.25) 4.42 (0.99-15.25) 1.31 (0.62-6.87)
N1 2.17 (0.51-11.14) 4.22 (1.33-11.14) 1.22 (0.51-4.12)
N2 4.20 (1.17-8.55) 6.17 (2.35-8.55) 1.80 (1.17-4.46)
N3 2.99 (1.31-8.06) 6.02 (4.96-8.06) 1.93 (1.31-2.99)
Nx/unknown 1.70 (0.93-8.64) 3.23 (1.17-8.64) 1.35 (0.93-2.08)
Treatment of BC
Chemotherapy¶
Yes 2.62 (0.51-13.75) 4.68 (1.08-13.75) 1.34 (0.51-4.46)
No 2.30 (0.62-15.25) 4.30 (0.99-15.25) 1.28 (0.62-6.87)
Hormonal therapy
Yes 2.58 (0.63-13.75) 4.45 (1.17-13.75) 1.33 (0.63-6.60)
No 2.29 (0.51-15.25) 4.43 (0.99-15.25) 1.28 (0.51-6.87)
(continued on following page)
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Total Left-Sided BC Right-Sided BC
RT
Regional RT
Yes 4.11 (1.17-10.81) 6.17 (2.35-10.81) 1.79 (1.17-4.46)
No 2.29 (0.51-15.25) 4.29 (0.99-15.25) 1.27 (0.51-6.87)
Abbreviations: ACE, acute coronary event; BC, breast cancer; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MHD, mean heart dose;
RT, radiotherapy.
*Risk factors according to Darby et al6 included: history of ischemic heart disease, history of circulatory disease other than ischemic heart disease, history of diabetes,
history of COPD, current smoker, and BMI $ 30 kg/m2. ACE was deﬁned according to Darby et al as a diagnosis of myocardial infarction (International Classiﬁcation of
Diseases, 10th Revision, codes 121 to 124), coronary revascularization, or death resulting from ischemic heart disease (codes 120 to 125).
†Women with a history of ischemic heart disease were deﬁned as those for whom myocardial infarction or angina was documented in their medical record.
‡Hypertension was considered when the systolic blood pressure was $ 140 mmHg and/or when the diastolic blood pressure was $ 90 mmHg.
§COPD of any Global Initiative on Obstructive Lung Disease class.
kDiabetes of any type.
¶Adjuvant systemic therapy was indicated in patients with high-risk node-negative tumors and in patients with node-positive disease. In 55 patients, detailed in-
formation about chemotherapy treatment was not clearly registered. In total, 248 patients received anthracyclines. In this series, 26 patients were treated with taxane-
based chemotherapy. Trastuzumab (n = 47) was recommended for all patients with tumors overexpressing the human epidermal growth factor receptor 2.
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Female patients with BC treated with RT after
breast-conserving surgery for stage I to III invasive 
adenocarcinoma or carcinoma in situ from January
 2005 to December 2008
(N = 1,137)
Analyzed
Patient cases (those who developed an ACE)
Noncases (those who did not)
Excluded
History of malignancy, prior thoracic RT, or
      treatment with neoadjuvant chemotherapy
























Fig A2. Distribution ofmean heart dose (MHD) for the entire population (N = 910;
median MHD, 2.37; standard deviation, 2.26; range, 0.51 to 15.25).
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Fig A4. Distribution of mean heart dose (MHD) for right-sided breast cancer























Fig A3. Distribution of mean heart dose (MHD) for left-sided breast cancer
(n = 451; median MHD, 4.44; standard deviation, 2.12; range, 0.99 to 15.25).
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Fig A6. Cumulative incidence of acute coronary events (ACEs) in the entire
























Fig A5. Relationship between mean heart dose (MHD) and percentage of acute
coronary events (ACEs) based on univariable analysis (ie, not corrected for age or
presence of cardiovascular risk factors). The linear trend line crosses the y-axis,
indicating ACEs not related to radiotherapy. Vertical bars indicate 95% CIs.
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